Mitochondrial Transplantation is Feasible in an In Vitro Neuronal Cell Model and Ameliorates Ischemia-Reperfusion Injury

Adam Carroll (1), Linling Cheng (1), William Riley Keeler (1), Bo Chang Wu (1), Anastacia Garcia (1), Muhammad Aftab (1), T. Brett Reece (1)

(1) University of Colorado Anschutz, Denver, CO



No disclosures





Introduction

- Ischemia-Reperfusion Injury (IRI) cause significant harm in aortic arch surgery, with potential to cause devastating neurologic outcomes
- Mitochondria (MT) play a key role in IRI, with initial oxygen-glucose deprivation depleting ATP, with subsequent production of reactive oxygen and nitrogen species leading to cell death
- Mitochondrial transplantation (MTR) has shown promise in other tissue models in attenuating ischemia-reperfusion injury





Aim

- Simulate in-vitro conditions mimicking ischemiareperfusion injury
- Harvest viable mitochondria from animal specimens
 - Determine optimal tissue for harvesting
- Demonstrate successful in-vitro uptake of mitochondria in non-ischemic & ischemic conditions
- <u>Apply mitochondrial transplantation to neuronal cells in</u> <u>an ischemia-reperfusion model to improve cell viability</u>



Methods & Results: IRI Condition Simulation

- HT-22, an immortalized mouse hippocampal cell line, cultured in 96 well plates
- Cells pre-cultured for 24 hours prior to ischemic conditions
- Ischemic conditions:
 - Oxygen-glucose deprived cell medium
 - Placement into hypoxia chamber at 0.1% O2
 - Control cells placed in new culture medium, returned to incubator
- Following oxygen-glucose deprivation (OGD) exposure, both groups of cells placed in new culture medium, returned to incubator for 24 hours
- Goal cell viability: 30-50% remaining cell viability as detected by MTS Assay
 - Tested at time points ranging from 8-48 hours
- 18 hours of OGD exposure was the optimal time point across multiple trials

Methods & Results: Mitochondrial Harvesting

- Tissue harvested from male mice at four different tissue sites: brain, heart, liver, skeletal muscle
- Tissue samples homogenized at varying time points, isolated with mitochondrial buffer
 - Optimal homogenization time point 30-40 seconds
- Excellent yield demonstrated from all tissue types
- MT stained with MitoTracker, successful uptake demonstrated viable mitochondria

1:5 dilution in PBS

1:10 dilution in PBS Fluorescent Microscope Imaging











Methods & Results: Mitochondrial Transplantation

- Tested mitochondrial transplantation of different tissue sources at two time points:
 - Pre-culture phase
 - Reperfusion phase





Methods & Results: Reperfusion MTR

Regardless of tissue type, MTR during reperfusion resulted in dose-dependent loss of viable cells for both control and OGD cells





Methods & Results: Pre-culture MTR

- At high doses, MTR killed both control and OGD cells
- However, at optimal concentrations MTR increased post-OGD cell viability
 - Repeat experiments performed with heart and muscle tissue (selected due to clinical potential) reinforced results







Neuronal cell viability post ischemia-reperfusion as detected from BCA assay. Mitochondrial transplantation (MTR) performed during pre-culture with mitochondria extracted from Muscle at specified concentrations and ratios above.



Methods & Results: Mitochondrial Incorporation

- To ensure mitochondria were successfully incorporated, performed immunofluorescence
- Red-stained mitochondria transplanted during pre-culture phase at different concentrations
- Following co-culture wells stained with DAPI to dye cell nucleus blue, and with MitoTracker Green to dye endogenous mitochondria green
- Demonstrated successful incorporation of exogenous mitochondria in both OGD and control conditions





Conclusions

- Mitochondria transplantation is feasible in an in-vitro neuronal cell model
- MTR performed during reperfusion results in dose-dependent loss in cell viability
- MTR during pre-culture increases cell viability after exposure to ischemic conditions
- Future Directions:
 - Attenuating response with introduction of pharmacologic agents targeting signaling mechanisms

Questions???